Although there is evidence that MAPK pathway blockade, such as MEK inhibitors, could enhance antitumor immune responses (28, 29), little is known about whether and how MAP3K1 itself modulate s the tumor microenvironment. Here, MAP3K1 is linked to neoplasm.